OC METRO CALENDAR

  • July 2014
    SuMoTuWeThFrSa
    293012345
    6789101112
    13141516171819
    20212223242526
    272829303112
    3456789
Add an event

PHARMACEUTICALS
Untitled Page

Irvine's Spectrum Pharmaceuticals acquires RIT Oncology

Company will market Non-Hodgkin's Lymphoma treatment in U.S.

By Kristen SchottPublished: March 16, 2009 09:49 AM

Irvine-based Spectrum Pharmaceuticals recently completed its acquisition of RIT Oncology LLC to commercialize Zevalin, a therapy for Non-Hodgkin's Lymphoma, in the United States.

Through the agreement, Spectrum holds full ownership of RIT and will be responsible for all future activities relating to Zevalin. The company will also book all of Zevalin's revenues.

“We are excited to have 100 percent ownership of Zevalin,” says the company's president, chairman and CEO, Rajesh C. Shrotriya, M.D. “Recent clinical data have dramatically underscored the clinical benefits of ZEVALIN in NHL (Non-Hodgkin's Lymphoma)."

PAGE TWO

Related headlines
San Clemente's STEMTech to Obama: What about adult stem cells?
Test results in: Clarient of Aliso Viejo's revenues soar
"OC METRO Minute," March 13: UCI's geriatrics program receives funding from Donald W. Reynolds Foundation
"OC METRO Minute," March 11: Epinex's diabetes monitoring device